background
respiratori
virus
common
caus
infect
immunosuppress
children
undergo
cancer
therapi
pulmonari
sequela
document
follow
respiratori
viral
infect
rvi
hematopoiet
stem
cell
transplant
hsct
recipi
howev
potenti
late
effect
children
undergo
nonmyeloabl
chemotherapi
investig
aim
evalu
longterm
pulmonari
morbid
respiratori
viral
infect
chemotherapi
children
acut
lymphoblast
leukemia
method
childhood
survivor
age
year
greater
month
posttreat
recruit
exclus
criteria
includ
hsct
proven
bacteri
fungal
respiratori
infect
treatment
subject
classifi
viral
control
group
accord
retrospect
medic
record
document
presenc
laboratoryproven
rvi
chemotherapi
symptom
questionnair
liverpool
isaac
lung
function
test
spirometri
plethysmographi
diffus
capac
forc
oscil
techniqu
atser
standard
perform
crosssect
time
recruit
result
fiftyfour
patient
viral
control
recruit
median
rang
age
year
year
posttherapi
abnorm
detect
individu
viral
control
common
dlco
impair
viral
control
reduc
respiratori
reactanc
hz
viral
control
children
rvi
chemotherapi
report
current
respiratori
symptom
particularli
wheez
odd
ratio
confid
interv
ci
p
cough
ci
p
differ
lung
function
test
observ
two
group
conclus
studi
found
children
rvi
chemotherapi
develop
longterm
respiratori
symptom
control
howev
differ
reach
statist
signific
differ
static
lung
function
found
two
group
overal
pulmonari
abnorm
andor
signific
ongo
respiratori
symptom
detect
nearli
third
survivor
treat
without
hsct
larger
prospect
studi
warrant
evalu
etiolog
clinic
signific
find
followup
studi
found
respiratoryrel
death
second
subsequ
malign
pulmonari
abnorm
detect
survivor
age
year
childhood
cancer
acut
lymphoblast
leukemia
common
carri
excel
prognosi
surviv
exceed
era
rise
cure
rate
late
pulmonari
effect
becom
increasingli
import
grow
popul
survivor
histor
research
focus
identifi
pulmonarytox
therapi
radiat
hematopoiet
stem
cell
transplant
hsct
inform
riskbas
pulmonari
followup
howev
respiratori
infect
also
signific
caus
pulmonari
morbid
treatment
particular
recent
studi
use
polymeras
chain
reaction
pcr
diagnost
found
respiratori
viral
infect
rvi
caus
febril
episod
children
undergo
chemotherapi
risk
sever
rvi
prolong
clinic
cours
higher
viral
load
gener
populationbas
studi
respiratori
syncyti
viru
rsv
rhinoviru
hrv
bronchiol
infanc
associ
subsequ
wheez
obstruct
defect
rvi
also
shown
precipit
late
airflow
declin
alloimmun
lung
syndrom
transplant
recipi
howev
longterm
pulmonari
sequela
rvi
children
undergo
chemotherapi
alon
investig
current
children
oncolog
group
cog
prescrib
recommend
longterm
pulmonari
function
screen
cohort
studi
aim
evalu
longterm
pulmonari
morbid
respiratori
viral
infect
chemotherapi
childhood
survivor
defin
static
lung
function
test
b
respiratori
symptom
beyond
month
posttherapi
hypothes
children
rvi
chemotherapi
would
demonstr
increas
respiratori
symptom
poorer
lung
function
compar
without
rvi
treatment
crosssect
cohort
studi
childhood
survivor
conduct
two
tertiari
pediatr
hospit
lung
function
assess
perform
compar
respiratori
outcom
children
without
proven
rvi
chemotherapi
ethic
approv
grant
sydney
children
hospit
network
human
research
ethic
committe
written
inform
consent
obtain
caregiv
particip
applic
childhood
survivor
primari
age
year
least
month
posttherapi
elig
studi
exclus
criteria
includ
pulmonarytox
therapi
prescrib
cog
longterm
followup
ltfu
guidelin
includ
craniospin
irradi
hsct
proven
bacteri
fungal
respiratori
infect
microbiolog
detect
sputum
chemotherapi
development
psychosoci
preclus
determin
oncologist
hospitalbas
oncolog
databas
review
patient
diagnos
primari
april
april
two
site
elig
patient
recruit
order
determin
onlin
random
sequenc
gener
classifi
viral
control
group
presenc
absenc
retrospect
particip
underw
assess
static
lung
function
test
forc
oscil
techniqu
fot
pre
postbronchodil
spirometri
bodi
plethysmographi
diffus
capac
carbon
monoxid
dlco
order
shown
b
respiratori
symptom
questionnair
particip
clinic
well
time
assess
fot
conduct
multifrequ
composit
waveform
hz
use
tremoflo
devic
thorasi
canada
accord
publish
recommend
isaac
questionnair
evalu
presenc
atop
diseas
includ
asthma
eczema
hay
fever
associ
symptom
lrsq
consist
question
across
domain
assess
respiratori
symptom
impact
child
famili
last
month
tabl
item
score
fivepoint
likert
scale
everyday
total
domain
score
overal
score
previous
recommend
snore
question
nighttim
domain
exclud
preval
day
night
exercis
symptom
includ
wheez
cough
dyspnoea
also
extract
respons
day
classifi
infrequ
respons
day
day
everyday
classifi
frequent
symptom
specif
analyz
consid
clinic
signific
note
cogltfu
guidelin
primari
outcom
measur
studi
total
respiratori
system
resist
hz
determin
fot
chosen
sensit
peripher
airway
function
base
previou
asthma
studi
primari
comparison
viral
control
group
made
use
student
test
continu
variabl
fisher
exact
test
categor
variabl
adjust
potenti
confound
multipl
regress
model
built
lung
function
symptom
outcom
use
forward
sequenti
note
liverpool
respiratori
symptom
questionnair
consist
eight
domain
assess
respiratori
symptom
impact
childfamili
last
three
month
frequenc
item
indic
fivepoint
likert
scale
assign
correspond
score
everyday
item
score
total
domain
score
overal
score
retain
p
valu
without
inflat
standard
error
greater
due
correl
year
posttherapi
age
test
p
age
test
alreadi
adjust
lung
function
endpoint
express
zscore
year
posttherapi
test
parsimoni
model
statist
perform
use
spss
version
ibm
signific
assign
p
children
treat
across
two
institut
elig
studi
patient
contact
enrol
figur
demograph
clinic
characterist
differ
patient
consent
declin
particip
tabl
baselin
characterist
studi
popul
n
display
tabl
viral
n
control
n
group
signific
differ
demograph
clinic
characterist
children
median
rang
age
patient
viral
group
n
median
rang
proven
rvi
chemotherapi
ten
accept
repeat
fot
spirometri
bodi
plethysmographi
dlco
data
obtain
f
g
u
r
e
consort
flow
diagram
recruit
patient
may
exclud
due
sever
criteria
note
suffici
patient
recruit
viral
group
patient
continu
randomli
select
adequ
control
recruit
period
addit
viral
patient
randomli
select
invit
particip
subject
respect
preval
wheez
cough
dyspnea
group
shown
tabl
viral
group
total
slightli
higher
overal
lrsq
score
knowledg
first
studi
investig
longterm
pulmonari
morbid
respiratori
virus
chemotherapi
childhood
cancer
survivor
compar
control
children
rvi
chemotherapi
ongo
respiratori
symptom
particularli
wheez
cough
although
result
reach
statist
signific
differ
static
lung
function
found
two
group
overal
pulmonari
abnorm
detect
nearli
third
survivor
evalu
year
posttherapi
note
patient
treat
without
pulmonarytox
therapi
recogn
cogltfu
guidelin
thu
receiv
routin
lung
function
screen
result
suggest
children
proven
rvi
chemotherapi
may
risk
develop
longterm
respiratori
symptom
threefold
increas
odd
wheez
nocturn
cough
observ
viral
group
report
higher
preval
nearli
symptom
lrsq
score
result
howev
statist
signific
studi
power
symptom
outcom
particularli
wheez
p
cough
p
moder
effect
size
consid
type
ii
error
suggest
larger
studi
warrant
futur
find
similarli
document
follow
infant
rsv
hrv
bronchiol
rvi
associ
subsequ
asthma
atopi
pathogenesi
earlylif
respiratori
virus
remain
unknown
studi
implic
excess
type
immun
aberr
lung
remodel
complex
howev
highlight
studi
suggest
inher
suscept
type
respiratori
episod
includ
bacteri
infect
import
viral
trigger
studi
one
child
posit
bronchodil
respons
atopi
low
viral
control
group
suggest
differ
phenotyp
diseas
cohort
older
sever
immunosuppress
hypothes
cancer
survivor
may
suffer
direct
tissu
damag
neuroimmun
modif
respiratori
mucosa
follow
rvi
howev
studi
requir
examin
role
pathogen
bacteria
infant
bronchiol
also
remain
question
caus
effect
whether
rvi
chemotherapi
predispos
respiratori
morbid
children
preexist
defect
suscept
rvi
static
lung
function
test
found
differ
viral
control
group
isol
import
neg
find
support
conserv
manag
rvi
cancer
therapi
suggest
viral
infect
confer
longterm
airflow
defect
possibl
immunosuppress
failur
mount
inflammatori
respons
protect
scar
lung
damag
howev
incongru
retrospect
studi
report
late
airflow
declin
associ
rvi
hsct
recipi
independ
alloimmun
lung
diseas
prolong
viralshed
subsequ
airway
inflamm
propos
mechan
injuri
find
suggest
pathogenesi
rvi
immunosuppress
cohort
uniqu
remain
poorli
understood
patient
rvi
may
sever
explan
preserv
lung
function
despit
increas
respiratori
symptom
firstli
reliabl
selfreport
symptom
may
question
howev
differ
patientreport
date
one
largest
crosssect
lung
function
studi
leukemia
survivor
report
examin
late
morbid
respiratori
virus
lung
function
data
crosssect
collect
includ
object
pulmonari
function
measur
patientrel
outcom
patient
homogen
cohort
primari
survivor
treat
contemporari
chemotherapi
protocol
exclus
children
expos
known
pulmonarytox
therapi
proven
bacterialfung
respiratori
infect
enabl
respiratori
virus
examin
minim
confound
howev
retrospect
studi
also
number
limit
rel
small
sampl
size
result
reach
statist
signific
thu
data
consid
hypothesisgener
suffici
patient
recruit
test
power
calcul
base
asthma
studi
studi
power
evalu
specif
risk
factor
virus
subspeci
preserv
parsimoni
model
covari
univari
p
could
retain
multivari
regress
analysi
thu
clinic
import
factor
age
diagnosi
retain
weak
predictor
small
sampl
size
requir
larger
studi
power
statist
model
meaning
test
impact
covari
retrospect
studi
reli
past
medic
record
microbiolog
test
sputum
sampl
collect
patient
time
therapi
data
use
classifi
viral
control
group
exclud
children
proven
respiratori
bacteri
fungal
infect
although
sputum
sampl
would
routin
test
patient
incomplet
medic
record
also
preclud
character
rvi
sever
upper
lower
tract
infect
furthermor
microbiolog
method
use
isol
respiratori
virus
variabl
cell
cultur
immunofluoresc
limit
diagnosi
specif
virus
hrv
hmpv
compar
newer
molecular
techniqu
thu
viral
cohort
may
repres
children
sever
infect
warrant
investig
virus
detect
microbiolog
method
avail
time
test
children
receiv
pulmonari
assess
prior
therapi
also
lack
longitudin
data
evalu
trend
pulmonari
function
chronolog
respiratori
symptom
respect
therapi
studi
found
children
respiratori
viral
infect
chemotherapi
develop
longterm
respiratori
symptom
control
howev
differ
statist
signific
differ
static
lung
function
outcom
found
two
group
overal
pulmonari
abnorm
andor
signific
ongo
respiratori
symptom
detect
nearli
third
survivor
treat
nonmyeloabl
chemotherapi
evalu
year
posttreat
find
warrant
futur
prospect
studi
etiolog
clinic
signific
therapeut
option
respiratori
complic
longterm
respiratori
followup
consid
survivor
facilit
earli
detect
manag
late
pulmonari
effect
sincer
grate
patient
famili
particip
studi
also
wish
thank
oncologist
sydney
children
hospit
network
valuabl
support
professor
jenni
peat
statist
advic
